- Poland
- /
- Professional Services
- /
- WSE:DGA
DGA Spólka Akcyjna Reports Full Year 2024 Earnings
DGA Spólka Akcyjna (WSE:DGA) Full Year 2024 Results
Key Financial Results
- Revenue: zł2.32m (down 76% from FY 2023).
- Net loss: zł2.94m (down from zł655.0k profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period

DGA Spólka Akcyjna shares are down 3.0% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with DGA Spólka Akcyjna.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:DGA
DGA Spólka Akcyjna
Operates as an advisory and investment company in Poland.
Flawless balance sheet and good value.
Market Insights
Weekly Picks

Looking to be second time lucky with a game-changing new product

Second order memory play likely to double in a year

Intuitive Machines: To The Moon and Beyond!
AppLovin’s AI Engine Is Printing Profit
Recently Updated Narratives

Partners Group Holding will achieve an 8.14% revenue rise over the next 5 years

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Niche global leader in BESS explosion protection
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

The $135 Billion Bet That Should Make Every Shareholder Nervous
